Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Jan 1.

Published in final edited form as: Cancer Lett. 2011 Sep 24;314(1):102–107. doi: 10.1016/j.canlet.2011.09.020

Fig. 2 — Bortezomib treatment of HNSCC cells induces complete autophagic flux. UMSCC-22A (A), 1483 (B), and UMSCC-1 (C) cells were left untreated, or treated for 24 hours with 0.1% DMSO, or for 24 or 48 hours with bortezomib, as in Figure 1. In addition, to assess for complete autophagic flux, cells treated with bortezomib for 24 hours were simultaneously treated with E64d (10 nM), leupeptin (Leu; 10 μM), and pepstatin A (PA; 10 μM). As a control, cells were also treated with the protease inhibitors alone. Following treatment, cell lysates were subjected to immunoblotting for LC3-II, Beclin-1, or β-actin. Densitometry was used to determine LC3-II/β-actin and Beclin-1/β-actin ratios. Similar results were obtained in 3 independent experiments.

Fig. 2 — Bortezomib treatment of HNSCC cells induces complete autophagic flux. UMSCC-22A (A), 1483 (B), and UMSCC-1 (C) cells were left untreated, or treated for 24 hours with 0.1% DMSO, or for 24 or 48 hours with bortezomib, as in Figure 1. In addition, to assess for complete autophagic flux, cells treated with bortezomib for 24 hours were simultaneously treated with E64d (10 nM), leupeptin (Leu; 10 μM), and pepstatin A (PA; 10 μM). As a control, cells were also treated with the protease inhibitors alone. Following treatment, cell lysates were subjected to immunoblotting for LC3-II, Beclin-1, or β-actin. Densitometry was used to determine LC3-II/β-actin and Beclin-1/β-actin ratios. Similar results were obtained in 3 independent experiments.